A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab

Grants and Contracts Details

StatusFinished
Effective start/end date12/16/198/21/23

Funding

  • PPD Investigator Services LLC: $82,865.00